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Background: Thrombolytic therapy (TT) for acute ischemic stroke (AIS) can provoke bleeding’s complication
depending on the ischemic lesion (IL) dimension. Inflammation involved in the setting of acute ischaemic stroke, is
associated with infarct size. We aimed to study the independent correlation and association between clinical panel
of routinely identified biomarkers, including inflammatory parameters, and cerebral IL dimension and site.
Results: We evaluated eleven biomarkers in 105 unrelated patients during their hospitalization after acute stroke
event. Our data indicate a significant association of: a) confluent IL size with 4th quartile of Erythrocyte
Sedimentation Rate (ESR) (OR = 5.250; 95% CI, 1.002 to 27.514) and an independent correlation with sex; b)
confluent IL size with 3rd quartile of fibrinogen (OR = 5.5; 95% CI, 1.027 to 29.451); c) confluent IL size with
3rd quartile of platelets (OR= 0.059; 95% CI, 0.003 to 1.175) and independent correlation with sex; d) smaller IL size
(OR = 5.25; 95% CI, 1.351 to 20.396) with 3rd quartile of albumin levels and nodular and parenchimal IL size with
2nd (OR = 0.227; 95% CI, 0.053 to 0.981), 3rd (OR = 0.164; 95% CI, 0.038 to 0.711) and 4th (OR = 0.205; 95% CI, 0.048
to 0.870) quartiles albumin levels; e) smaller IL size with 3rd quartile triglycerides (TG) levels (OR = 9; 95% CI, 2.487
to 32.567) and an independent correlation with anterior location. Smaller IL size, anterior AIS turned out to be
independently correlated with high serum albumin levels. Finally, high INR and PTT values were associated with
worse NIHSS clinical outcomes in contrast to that observed with higher albumin level.
Conclusions: We provide evidence of routine biomarkers levels correlation with acute IL size, independently of age
and sex. In addition, we highlight the importance of differentiation of biomarkers normal interval levels for further
improvement not only of the clinical decision making but also in post-acute clinical outcome management.
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Stroke remains the third leading cause of death and the
leading cause of severe disability in the United States,
Europe and portions of Asia in young [1] and elderly
people [2-4]. Actually, the successful therapy for acute
stroke is thrombolysis and bleeding is often a complica-
tion that can also depend on the lesion size [5]. Recent
report shows that inflammation in the setting of acute
ischaemic stroke (AIS) is associated with infarct size,
supporting the hypothesis that inflammation in acute* Correspondence: cvecchione@unisa.it
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reproduction in any medium, provided the orstroke primarily reflects an acute phase response deter-
mined by the degree of cerebral injury. Acute inflamma-
tion that develops following the initial ischemic episode
is a major mechanism by which cells in the penumbra
degenerate and the participation of inflammatory factors
could be associated to the presence of early neurological
deterioration and infarct volume [6].
The definition of the available independent correlates
of serum biomarkers with cerebral lesions and sites
could further help in the clinical practice for the acute
ischemic stroke management reducing complications
following acute treatment [7]. Despite it, the biomarkers
serum levels were hypothesized to be independently cor-
related with cerebral lesion sites and size in AIS, but sol Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[8]. Our aim was to characterize the clinical biomarkers
routine panel correlation and association with cerebral
lesion sites and dimensions in AIS patients, evaluating
the possible association with clinical outcome.Results
Our study population includes 105 patients: 59 (56.19%)
males and 46 (43.81%) females. The mean age of patients
was 63.3 years (SD ± 14 years, range 46–78 years).
9 patients were excluded because of missing data on
biomarkers. Thus, the final study population includes
96 participants. Table 1 reports descriptive statistics for
classical cerebrovascular risk factors stratified by gender.
In particular, women are a bit older than man and their
levels of erythrocyte sedimentation rate (ESR), high
density lipoprotein (HDL), glucose, hypertension preva-
lence and anterior stroke site distribution are increased
as compared to men. In contrast, serum triglycerides
(TG), partial thromboplastin time (PTT) and low density
lipoprotein (LDL) values of women are lower comparedTable 1 AIS variables characteristics in the study population
Variable name (Units) Total (n = 105) N**
Mean* ± SD
NIHSS at 7 days 6.47 ± 0.6 105
Age (years) 63.3 ± 14 105
Body Mass Index (Kg / m2) 25.5 ± 3.7 79
Hypertension (%) 55.2 58
Diabetes mellitus (%) 39.1 41
Previous myocardial infarction (%) 14.3 15
Current smoking (%) 17.1 18
SBP (mmHg) 142.9 ± 25.7 105
DBP (mmHg) 81.03 ± 13.8 105
MAP (mmHg) 101.7 ± 16.4 105
Heart rate (bpm) 72.8 ± 12.9 105
AIS site (anterior%) 59.1 62
Glucose (mg / dL) 130.4 ± 52.4 104
Albumin (g / dL) 3.2 ± 0.6 96
TG (mg / dL) 129.4 ± 71.4 103
TC (mg / dL) 179.7 ± 43.2 103
LDL (mg / dL) 122.9 ± 41.3 102
HDL (mg / dL) 41.70 ± 11.4 102
INR (ratio) 1.15 ± 0.5 105
PTT (sec) 30.9 ± 5.7 104
Platelets (value x 10.e3 / uL) 262.2 ± 92 100
ESR (mm) 21.3 ± 19.8 99
Fibrinogen (mg / dL) 398.1 ± 137.1 98
All values are unadjusted means ± standard deviation for continuous trait and perc
of samples for each biomarker analyzed.to men. There are no significant differences between the
sexes for other variables. The relationship between
plasma biomarkers levels and AIS cerebral lesion site
and lesion dimension revealed as regression coefficients
with relative p-values are shown in Table 2.
As anticipated by significant magnitudes and directions
between biomarkers and lesion sites revealed by regres-
sion coefficients, given the random variance introduced
by different levels of biomarkers among AIS patients,
further relationship between biomarker’s quartiles: first
quartile (Q1) used as reference to second quartile (Q2),
third quartile (Q3), forth quartile (Q4) and lesion loca-
tion and size were assessed.
ESR serum levels were independently correlated with
sex (b = + 0.65, S.E. = 0.24, p = 0.008) and D3 (b = + 0.53,
S.E. = 0.27, p = 0.0045) lesion (Table 2). In quartile ana-
lysis D3 lesion remained associated with Q4 (OR, 5.250;
95% CI, 1.002 - 27.514 ) of ESR (Table 3) (Figure 1).
Fibrinogen serum levels were independently correlated
with D3 (b = + 0.58, S.E. = 0.27, p = 0.040) lesion
(Table 2). Lesion D3 remained associated with Q3 (OR,
5.500; 95% CI, 1.027 - 29.451 p=0.040) of fibrinogen inWomen N Men N
Mean* ± SD Mean* ± SD
8.4 ± 0.9 46 5.0 ± 0.7 59
67.2 ± 14.8 46 60.2 ± 12.7* 59
25.2 ± 4.1 20 25.7 ± 3.6 59
69.5 32 44.1* 26
41.3 19 37.3 22
15.2 7 13.6 8
10.8 5 22* 13
142.6 ± 24.4 46 143.1 ± 26.8 59
79.2 ± 14 46 82.3 ± 13.6 59
100.3 ± 16 46 102.6 ± 16.7 59
70 ± 13.6 46 72 ± 12.6 59
71.7 33 49.2* 29
140.7 ± 57.4 46 122.1 ± 47.6* 58
3.2 ± 0.7 42 3.4 ± 0.7 54
118.1 ±72.1 46 137.9 ± 71.7* 57
179.9±42.7 46 179.6 ± 44.7 57
116.3 ± 37.7 46 127.9 ± 44.6* 56
45.6 ± 10.1 46 38.8 ± 11.9* 56
1.20 ± 0.8 46 1.08 ± 0.1 59
28.4 ± 20.6 46 30.8 ± 4.1 58
302.8 ± 108.4 46 234.1 ± 71.5* 54
26.8 ± 24.3 45 17.3 ± 16.1* 54
396.1 ± 177.5 44 390.6 ± 123.8 54
ent for non-continous trait.* significantly different from women. **N = number
Table 2 Independent correlates of principal biomarkers in AIS
Biomarker ESR (mm) Fibrinogen (mg / dL) Platelets (val. x 10.e3 / uL) Blood albumin (g / dL) Triglycerides (mg / dL) Glucose (mg / dL) HDL (mg / dL)
b ± S.E. p b ± S.E. p b ± S.E. p b ± S.E. p b ± S.E. p b ± S.E. p b ± S.E. p
Site + 0.48 ± 0.23 0.044 + 0.63 ± 0.24 0.008*
Sex - 0.65 ± 0.24 0.008* - 0.81 ± 0.23 0.001* - 0.66 ± 0.23 0.005*
D1 - 0.02 ± 0.01 0.029 - 0.03 ± 0.008 0.002* + 0.02 ± 0.008 0.018*
D2 - 0.68 ± 0.31 0.035 - 0.59 ± 0.25 0.020 + 0.68 ± 0.25 0.009*
D3 + 0.53 ± 0.27 0.054* + 0.58 ± 0.27 0.040* - 0.55 ± 0.27 0.042
D4 - 0.98 ± 0.47 0.041
No independent correlates were identified for dependent variables of TC, LDL, INR; * p - value < 0.01; D1 = points (< 1.5 cm], D2 = nodular dimensions [1.5 - 3 cm] & parenchymal dimensions (> 3 cm), D3 = confluent





















Table 3 Multivariate testing: OR (95% CI) to the first quartile of biomarkers investigated vs stroke lesion site (anterior
vs posterior) & stroke lesion dimensions
Variable (Units) / Quartiles Site D1 D2 D3 D4
(OR; 95% CI) (OR; 95% CI) (OR; 95% CI) (OR; 95% CI) (OR; 95% CI)
ESR (mm)
Q1 (< 10) n = 23 1 1 1 1 1
Q2 [10 – 16) n = 30 0.650 (0.212-1.993) 0.473 (0.149-1.501) 2.115 (0.666-6.715) 2.625 (0.478-14.428) 7.981 (0.383-166.240)
Q3 [16 – 30) n = 19 0.758 (0.218-2.632) 0.945 (0.277-3-230) 1.319 (0.380-4.577) 2.800 (0.452-17.318) 6.714 (0.283-159.527)
Q4 [> 30) n = 27 1.040 (0.339-3.190) 0.765 (0.246-2.381) 1.538 (0.488-4.853) 5.250 (1.002-27.514)* 0.855 (0.015-48-430)
Fibrinogen (mg/dL)
Q1 (< 303) n = 24 1 1 1 1 1
Q2 [303 – 368) n = 25 1.333 (0.415-4.281) 1.366 (0.411-4.539) 0.708 (0.203-2.470) 2.750 (0.479-15.794) 0.958 (0.057-16.243)
Q3 [368 – 462) n = 24 0.824 (0.242-2.797) 1.214 (0.358-4.124) 0.667 (0.190-2.338) 5.500 (1.027-29.451)* 2.091 (0.177-24.734)
Q4 [> 462) n = 25 2.167 (0.682-6.883) 1.619 (0.493-5.319) 0.500 (0.147-1.697) 4.278 (0.789-23.193) 2.000 (0.169-23.623)
Platelets (value x 10.e3/uL)
Q1 (< 189) n = 25 1 1 1 1 1
Q2 [189 – 256) n = 25 0.434 (0.138-1.371) 0.826 (0.246-2.776) 1.000 (0.291-3.437) 1.000 (0.278-3.598) 13.683 (0.674-277.964)
Q3 [256 – 323) n = 25 0.519 (0.167-1.611) 1.417 (0.444-4.521) 0.583 (0.178-1.906) 0.059 (0.003-1.175)* 3.122 (0.114-85.732)
Q4 [> 323) n = 25 1.000 (0.330-3.033) 1.962 (0.621-6.193) 0.495 (0.153-1.606) 2.032 (0.608-6.797) 1.000 (0.018-56.631)
Blood Albumin (g/dL)
Q1 (< 2.9) n = 25 1 1 1 1 1
Q2 [2.9 – 3.4) n = 24 1.504 (0.488-4.639) 3.150 (0.815-12.168) 0.227 (0.053-0.981)* 1.059 (0.306-3.658) 5.677 (0.243-132.298)
Q3 [3.4 – 3.8) n = 22 1.273 (0.403-4-19) 5.250 (1.351-20.396)* 0.164 (0.038-0.711)* 0.406 (0.091-1.817) 3.558 (0.129-98.252)
Q4 [> 3.8) n = 25 0.402 (0.102-1.349) 3.500 (0.921-13-307) 0.205 (0.048-0.870)* 0.643 (0.173-2.388) 7.933 (0.366-172.044)
Triglycerides (mg/dL)
Q1 (< 78) n = 25 1 1 1 1 1
Q2 [78 – 111) n = 26 2.844 (0.913-8.861) 1.474 (0.398-5.452) 0.833 (0.218-3.179) 0.273 (0.072-1.034) 0.958 (0.124-7.383)
Q3 [111 – 162) n = 26 1.778 (0.579-5.457) 9.000 (2.487-32.567)* 0.132 (0.037-0.471)* 0.273 (0.072-1.034) 0.460 (0.039-5.418)
Q4 [> 162) n = 26 0.323 (0.084-1.237) 1.474 (0.398-5.454) 0.679 (0.183-2.510) 0.273 (0.072-1.034) 0.460 (0.039-5.418)
OR = odds ratio; 95% CI = odds ratio confidence interval. ORs are adjusted for age and sex; * D1 = points (< 1.5 cm], D2 = nodular dimensions [1.5 - 3 cm] &
parenchymal dimensions (> 3 cm), D3 = confluent dimensions, D4 = non confluent dimensions; * p-value < 0.05 compared with the reference group Q1;
** N = number of samples = 96.
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levels were independently correlated with sex (b = + 0.81,
S.E. = 0.23, p = 0.001) and D1 (b = + 0.02, S.E. = 0.01,
p = 0.003), D2 (b = + 0.68, S.E. = 0.31, p = 0.035) lesions
(Table 2). In quartile analysis only D3 lesion remained
associated with Q3 (OR, 0.059; 95% CI, 0.003 - 1.175 ) of
platelets (Table 3) (Figure 1).
Albumin levels were independently correlated with site
(b = − 0.48, S.E. = 0.23, p = 0.0436) and D1 (b = − 0.03,
S.E. = 0.008, p = 0.002), D2 (b = − 0.59, S.E. = 0.25,
p = 0.020), D3 (b = −0.55, S.E. = 0.27, p = 0.042), D4
(b = − 0.98, S.E. = 0.47, p = 0.041) size (Table 2); lesion
D1 size remained associated with Q3 (OR, 5.250; 95% CI,
1.351 - 20.396 ) of serum albumin level, whereas lesion
D2 remained associated with Q2 (OR, 0.227; 95% CI,
0.053 - 0.981), Q3 (OR, 0.164; 95% CI, 0.038 - 0.711 ) and
Q4 (OR, 0.205 ; 95% CI, 0.048 - 0.870) (Table 3)
(Figure 1).TG levels were independently correlated with site
(b = + 0.63, S.E. = 0.24, p = 0.008) and D2
(b = + 0.68, S.E. = 0.25, p = 0.009) size (Table 2).
Lesion D1 was associated with Q3 (OR, 9.000; 95% CI,
2.487 - 32.567) of TG and lesion D2 size remained
associated with Q3 (OR, 0.132; 95% CI, 0.037 - 0.471 )
(Table 3) (Figure 1).
HDL serum levels were independently correlated with
sex (b = + 0.66, S.E. = 0.23, p = 0.005) and glucose levels
were independently correlated with D1 (b = + 0.02,
S.E. = 0.008, p= 0.018) lesion (Table 2).
In quartile analysis, both HDL and glucose as well as
PTT, international normalized ratio (INR), LDL and
total cholesterol (TC) (data not shown) were not signifi-
cantly associated with lesion size dimension.
Finally, high INR (NIHSS ≥ 14, p = 0.01) and high PTT
(NIHSS ≥ 7, p = 0.001) were associated with worse clin-

































































































































Figure 1 Biomarkers OR stratified by AIS lesion site and dimension (D1 - D4). Patients in Q1 were used as a reference in each group. All
values were adjusted for age and sex. *Significantly different from Q1.
Kisialiou et al. Immunity & Ageing 2012, 9:22 Page 5 of 10
http://www.immunityageing.com/content/9/1/22serum level was associated with better clinical outcome
(NIHSS < 7, p = 0.006) at 7 days.
Discussion
The use of biomarkers has made a strong impact in
understanding of the pathophysiology of stroke and the
approach to its treatment [9]. Actually, the only approved
pharmacological therapy for acute stroke is thrombolysis
which acts mediating recanalization and often induces
secondary hemorrhage depending on the IL size [10].
The identification of clinical biomarkers of acute cerebralischemia would facilitate the use of time-sensitive reper-
fusion strategies offering a potential role for improved
treatment selection and individualization of therapy.
Brain inflammation contribute to the pathophysiology
of cerebral injury in acute stroke and it has been reported
to be associated with infarct size [11,12]. We show that
high ESR value is associated with larger infarct size. ESR
values observed soon after AIS may reflect a degree of
acute phase response in early phase of AIS and extent of
local brain damage [13]. The acute phase response fol-
lows tissue injury and contributes to its exacerbation
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inducing erythrocyte aggregation [14]. Thus, ESR is a
measure of the acute phase response and its monitoring
at the time of admission may serve as a marker for severity
after AIS.
In addition to ESR we found even normal-high
fibrinogen serum levels associated with larger infarct size.
Fibrinogen, previously described as an independent
coronary heart disease risk factor is now considered an
inflammatory marker modulating the balance between
hemostasis and thrombosis, coagulation and fibrosis,
protection from infection and extensive inflammation
[15]. A plasma fibrinogen measurement is a clinical
standard to evaluate bleeding disorder or thrombotic
episode. Apart from its pivotal role in thrombogenesis,
inflammation, immune responses and atherogenesis, it is
also a prominent acute-phase reactant. Transiently ele-
vated plasma fibrinogen levels have been described in
acute stroke. Fibrinogen acts also as bridge between
adjacent platelets to generate a platelet aggregate [15].
Circulating platelets have been recognized for their im-
portance in modulating recurrent stroke and we show
that high-normal platelet serum levels are associated
with large infarct dimension. Circulating platelets play an
important role in the development, progression, and
resolution of stroke, not only depending on their direct
effects on endothelium but also by acting as a connection
for other cells in vascular system. In particular, following
vessel injury platelets interact with damaged endothelium
and release factors stored in granules that play a role in
recruitment of leukocytes, additional platelets, or other
blood cells to the vessel wall [16]. The interaction among
these factors is critical for hemostasis, host defense and
represents the mechanism used by platelets to induce
atherothrombosis and inflammatory events leading to
ischemic stroke.
Among the biochemical parameters used routinely
we show that normal-high albumin levels characterize
AIS patients with minor lesion size whereas low-normal
albumin levels were associated with more extended
lesion. Experimental studies showed that high-dose or
moderate-dose of human albumin therapy, after stroke
onset, is highly effective in improving neurological status
and in reducing infarction volume and extent of brain
swelling [17-19]. Albumin is the most abundant protein
found in plasma, functioning as a carrier molecule, main-
taining oncotic pressure and acting as a major antioxidant
defender in inflammatory process [18]. In addition,
serum albumin level is one of the biochemical markers of
nutritional status and it has been reported that protein-
energy malnutrition after acute stroke is a risk factor for
poor outcome worsening the prognosis [20]. These ex-
perimental evidences are in agreement with our finding
observed in humans showing that low serum levels ofalbumin are associated with elevated NIHSS score at
7 days, suggesting that high albumin is neuroprotective
in ischemic stroke for both lesion gravity and clinical
outcome [21,22].
Finally, we found that normal-high levels of TG are
associated with smaller infarct size. The role of TG in
the risk of ischemic stroke remains controversial. A
strong association was found between elevated levels of
TG and increased risk of ischemic heart disease [23]. In
addition, increased levels of nonfasting TG were corre-
lated with an incidence of ischemic stroke [24]. Nonfast-
ing TG indicate the presence of increased levels of
remnants from chylomicrons and very low-density lipo-
proteins which penetrate the arterial endothelium and
may get trapped within the subendothelial space, poten-
tially leading to the development of inflammation in
atherosclerosis.
In addition, both high INR and PTT were associated
with worse NIHSS outcome, suggesting their neuropro-
tective effect at low levels in acute stroke patients.
Regarding the independent correlation to lesion site
we observed high-normal significant values of albumin
and TG serum levels and we were not able to establish
the association between quartiles of other biomarkers
and lesion site.
Conclusions
Our results show the association of some inflammatory
biomarkers with ischemic lesion size suggesting the con-
tribution of inflammation as a prognostic indicator for
the development of clinical complications following cere-
bral acute events. Actually, there is a substantial interest
in the use of biomarkers panel to identify subjects at
higher risk for the development of complications follow-
ing thrombolysis therapy. The present study examines
the association between biomarkers, paying attention, in
particular, to the hypothesis that different plasma levels
of biomarkers assessed at baseline in subjects affected by
AIS could be predictive for developement of both size
lesions and clinical outcome. These results further con-
firm our assumption that multivariate analyses of rele-
vant biomarkers are necessary to reduce the risk of
inaccurate prognosis. It is important to emphasize that
considering biomarker’s normal range still does not allow
to exploit their clinical potential in management of AIS.
We highlight the importance of differentiation of normal
interval levels of serum biomarkers to improve not only
clinical decision making but also post acute clinical
outcome.
Exploratory studies within clinical trials are necessary
before blood markers of cerebral tissue damage can be
recommended as surrogate endpoints. In other words
it is essential to increase the number of informative
markers and to assess their relative contributions to
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and stratification of patients for stroke therapy in a prac-
tical and cost-effective manner.
Methods
Study population
105 consecutive AIS patients admitted to the local
Stroke Unit of the Mediterranean Neurological Institute
Neuromed – Institute of Research and Care, Molise,
Italy were included prospectively in the study. Data col-
lection consisted of a physical and neurological examina-
tions and evaluations at the study clinic, urine test, blood
draws. Data about biological determinations were col-
lected from medical records. In particular, we evaluated
glucose [25], albumin [26], TG, TC, LDL, HDL [27,28],
INR, PTT, platelets [29], ESR [30], fibrinogen [31,32].
Fasting blood samples were collected at admission at
Stroke Unit in approximately ten minutes. We assessed
the participants for current smoking, antihypertensive
medication, hypoglycemic medication, myocardial infarc-
tion history. The inclusion criteria for participation in
the study was a diagnosis of acute ischemic stroke (ICD
IX 434.91) admitted within the first 24 hours after symp-
tom onset. Patients were excluded if they had a clinical
record and documentation of the following: ischemic
conditions including acute myocardial ischemia, per-
ipheral vascular disease or shock, kidney failure, known
inflammatory or malignant disease, transient ischemic
attack, hemorrhagic stroke and finally a diagnosis other
than stroke (e.g., migraine) or epileptic seizure. All respon-
dents signed informed consent of the Mediterranean
Neurological Institute Neuromed – Institute of Research
which authorized the data treatment collected from all
the patients during hospitalization.
Stroke work-ups
All patients underwent brain MRI [1,5 T General Electric
(GE), HDXt scanner] with diffusion-weighted imaging
(DWI) that was reviewed by two neuroradiologists in AIS
who were blinded to the clinical details and blood bio-
markers determinated. The ischemic lesions have been
considered according to size following the scheme: D1 –
points (< 1.5 cm), D2 – nodular dimensions [1.5 - 3 cm]
& parenchymal dimensions (> 3 cm), D3 – confluent
dimensions, D4 – non confluent dimensions; and loca-
tion anterior or posterior due to the diagnostic criteria
[33]. In the case of multiple event the first event was used
in the analysis. During the hospitalization, all patients
with AIS had an extensive workup including transthoracic
echocardiography carotid ultrasonography if required,
computed tomography n = 10 (9.5%) or magnetic reson-
ance angiography n = 91 (86.7%): CT or MRI angiography,
and transthoracic saline contrast echocardiography. Blood
pressure was measured twice in the supine position inthe right upper arm using automated device [34,35],
average of two measurements was used for analysis.
Mean arterial pressure (MAP) was calculated as 1/3 sys-
tolic blood pressure (SBP) + 2/3 diastolic blood pressure
(DBP). Hypertension was defined as DBP ≥ 90 mmHg
and/or a SBP ≥ 140 mmHg or use of anti-hypertensive
medication. Diabetes mellitus at admission was defined
by one or two common criteria: high glucose serum
levels or use of glucose lowering medication.
Image analyses
Patients were investigated at admission with a 1,5 T
magnetic resonance scanner using a protocol including
DWI [36] ( TR / TE: 7000 /98 msec, Matrix: 128 x 128,
slice thickness / gap: 5.0 / 1.0 mm) and fluid attenuated
inversion recovery imaging (TR / TE / TI: 8000 / 120 /
2000 msec, Matrix freq / phase: 288 x 192, slice thickness
5.0 / 1.0 mm ), to perform 20 to 23 slices. DWI was per-
formed with 2 levels of diffusion sensitization (b.0 and
1000 sec / mm2). DWI lesion volumes were measured
with MIPAV software (Medical Image Processing, Ana-
lysis and Visualization, version 3.0, National Institutes
of Health, Bethesda, MD) and processed with Apparent
Diffusion Coefficient (ADC) maps (Figure 2).
Two raters outlined regions of acute diffusion abnor-
mality on the b.1000 image, consulting apparent diffusion
coefficient and FLAIR sequences to distinguish acute
from non-acute diffusion change. Acute diffusion lesions
were defined on a slice-by-slice basis using a semi-
automatic threshold approach by a rater blinded (BHB) to
all clinical information [37]. Lesion volumes were calcu-
lated by multiplying slice thickness by the total lesion area.
Biochemical assessment – laboratory analysis
Fasting blood samples were collected by venipuncture
at admission to the Stroke Unit. Routine Dimension
AX-R/Siemens, Stratus/Siemens, Adivia 120/Siemens,
Coulter Maxm, Bct/Siemens were utilized for the deter-
mination of eleven plasma biomarkers values: glucose
(mg / dL), albumin (g / dL), TG (mg / dL), TC (mg / dL),
LDL (mg / dL), HDL (mg / dL), INR (ratio), PTT
(seconds), platelets (value x 10.e3 / uL), ESR (mm),
fibrinogen (mg / dL) routinely using standard assays [38].
All analyses were carried out at the same time by a
biologist blinded to the diagnosis.
NIHSS
Stroke severity was measured at the time of admission
and after 7 days with the National Institutes of Health
Stroke Scale (NIHSS). The NIHSS is a 15-item neuro-
logic examination stroke scale used to provide a quanti-
tative measure of stroke-related neurologic deficit by
evaluating the effect of acute ischemic stroke on the
levels of consciousness, language, neglect, visual-field
Figure 2 Axial diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) maps in grey level and multi-chromatic that
show acute ischemic lesion (D1 - D4): a lesion that is hyperintense on DWI and hypointense on ADC map is a characteristic magnetic
resonance imaging (MRI) finding in acute ischemic infarction. Note: regions of interest (ROI) positioned on normal parenchyma (1, green)
and on acute ischemic areas (2,3, purple/red) in order to demonstrate hyperintensity on DWI corresponding to hypointensity on the ADC map in
grey level. Multi-chromatic ADC maps show blue/light green areas in correspondence of ischemic lesions.
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dysarthria, and sensory loss. Each item is scored with 3
to 5 grades, with 0 as normal and the final total score
having a potential range of 0 to 42, with higher scores
indicating greater stroke severity. Stroke severity mea-
sured at 7 days from admission by NIHSS was used to
assess the independent association between variables
(biomarkers) and outcome.
The mean NIHSS score evaluated at admission and at
7 days, all patients were divided to the one week evalu-
ated NIHSS severity into groups with mild neurological
deficits with NIHSS < 7; a group with severe neuro-
logical deficits with NIHSS ≥ 7. Finally, we divided the
group with sever deficits in two subgroups: 7 ≤ NIHSS <
14, 14 ≤ NIHSS [39].
Statistical analysis
Of the total sample, 62 patients (59.05%) were assessed
with anterior stroke, 43 patients (40.95%) were assessedwith posterior stroke: 9 patients ( 8.57% ) dead during
the hospitalization, 6 patients ( 5.71% ) had repeated AIS
event during their stay in the hospital.
The distribution of different lesions was as following:
D1 lesions – 33 patients ( 31.43% ); D2 lesions – 18
patients ( 17.14% ) with nodular dimensions [1.5 – 3 cm]
and 53 patients ( 50.48% ) with parenchymal dimen-
sions (> 3 cm); D3 lesions – 23 patients ( 21.90% ); D4
lesions – 6 patients ( 5.71% ).
The mean NIHSS score (±SD) evaluated at 7 days was
6.47 ± 0.6. The distribution of different NIHSS severity
groups at one week from admission was as following:
NIHSS < 7 (n=70; 67.3%); NIHSS ≥ 7 (n=34; 32.7%); 7 ≤
NIHSS < 14 (n = 16; 15.4%); NIHSS ≥ 14 (n = 18, 17.3%).
χ2 test and t-test for independent samples to compare
subgroups of patients were used. Multiple linear regres-
sion models were fitted to examine the independent cor-
relation of biomarkers levels with cerebral lesion site
and size, sex and age. For these analyses the biomarker
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residuals. The normality of residuals was tested using a
Shapiro - Wilk test.
Regression models assessing the blood markers quar-
tiles difference from quartile one versus cerebral lesion
size and sites were realized. The quartiles were used due
to the large skew in the distribution resulting from indi-
viduals. Regression models assessing the blood markers
quartiles versus cerebral lesion size and sites were fitted
for all biomarkers outcomes and adjusted for age and
sex. These findings were non dramatically affected by
excluding antihypertensive medication, hypoglycemic
medication from models, but by different values of effi-
cacy, compliance, and dosage among treated individuals
(data not shown). Each model significant P - value <
0.05 compared with the reference group of quartile one
and relative Odds Ratios (OR) were found. The analyses
were executed utilizing the SAS Statistical System 8.2.
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